Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Contact information

Email
Daniel.Jenkin@ndm.ox.ac.uk

ORCID
https://orcid.org/0000-0003-3088-310X

Research groups

Daniel Jenkin

MBChB, MSc, DTM&H, MRCP

Clinical Research Fellow

Websites

Research Gate Profile

Recent publications

Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial.
Journal article

Jenkin D. et al, (2023), The Lancet. Infectious diseases
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials
Journal article

Voysey M. et al, (2023), Clinical and Experimental Immunology
Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial
Journal article

Madhavan M. et al, (2022), eBioMedicine, 85, 104298 - 104298
Safety and immunogenicity of a simian-adenovirus-vectored rabies vaccine: an open-label, non-randomised, dose-escalation, first-in-human, single-centre, phase 1 clinical trial
Journal article

Jenkin D. et al, (2022), The Lancet Microbe, 3, e663 - e671
Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment.
Journal article

Folegatti PM. et al, (2022), Vaccine, 40, 5248 - 5262

More publications